Cargando…

Clinical Benefits of Oral Anticoagulant Use in Cancer Patients at Increased Risk for Venous Thromboembolism per Khorana Index

BACKGROUND: Cancer patients are at increased risk for venous thromboembolism (VTE) due to cancer-induced hypercoagulability. However, current guidelines do not routinely recommend prophylactic use of oral anticoagulants to prevent VTE in cancer patients. OBJECTIVE: To evaluate the efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Yeo Jin, Choi, Yong Won, Chae, Jung-woo, Yun, Hwi-yeol, Shin, Sooyoung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114826/ https://www.ncbi.nlm.nih.gov/pubmed/33994816 http://dx.doi.org/10.2147/RMHP.S306760

Ejemplares similares

Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma
por: Sanfilippo, Kristen M., et al.
Publicado: (2022)

Validation of the Khorana Venous Thromboembolism Risk Score in Japanese Cancer Patients
por: Akasaka-Kihara, Fumie, et al.
Publicado: (2021)

Evaluation of the Khorana, PROTECHT, and 5‐SNP scores for prediction of venous thromboembolism in patients with cancer
por: Guman, Noori A. M., et al.
Publicado: (2021)

Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer
por: Piver, Rachael N., et al.
Publicado: (2023)

The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis
por: Mulder, Frits I., et al.
Publicado: (2019)

Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy
por: Overvad, Thure Filskov, et al.
Publicado: (2022)

The role of direct oral anticoagulants in venous thromboembolic disease in gynecologic cancer
por: Park, Jeong-Yeol
Publicado: (2019)

Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score
por: Rupa-Matysek, Joanna, et al.
Publicado: (2017)

Direct oral anticoagulants and venous thromboembolism
por: Franchini, Massimo, et al.
Publicado: (2016)

Retrospective Cohort Study of Venous Thromboembolism Rates in Ambulatory Cancer Patients: Association With Khorana Score and Other Risk Factors
por: Austin, Keziah, et al.
Publicado: (2019)

Using the Khorana risk score to predict venous thromboembolism and overall survival in a cohort of Hispanic patients with solid malignancies
por: Ramos-Esquivel, Allan, et al.
Publicado: (2022)

Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism
por: Fang, Margaret C., et al.
Publicado: (2021)

Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018)

Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan
por: Nakamura, Mashio, et al.
Publicado: (2017)

Direct oral anticoagulants for unusual‐site venous thromboembolism
por: Riva, Nicoletta, et al.
Publicado: (2021)

Direct Oral Anticoagulants for Cancer-Associated Venous Thromboembolism
por: Masini, Marta, et al.
Publicado: (2023)

Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism
por: López-Núñez, Juan J., et al.
Publicado: (2019)

Validation of the Khorana Score to Assess Venous Thromboembolism and Its Association with Mortality in Cancer Patients: A Retrospective Community-based Observational Experience
por: Ahmed, Gulrayz, et al.
Publicado: (2020)

Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy
por: Finks, Shannon W., et al.
Publicado: (2016)

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism
por: Yhim, Ho-Young, et al.
Publicado: (2014)

Direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer
por: Planquette, Benjamin, et al.
Publicado: (2019)

New anticoagulants for the prevention of venous thromboembolism
por: Becattini, Cecilia, et al.
Publicado: (2010)

New anticoagulants for the treatment of venous thromboembolism
por: Fernandes, Caio Julio Cesar dos Santos, et al.
Publicado: (2016)

Extended anticoagulation for unprovoked venous thromboembolism
por: Castellucci, Lana A., et al.
Publicado: (2018)

Venous Thromboembolism While on Anticoagulation With Apixaban
por: Mazahreh, Farah, et al.
Publicado: (2021)

Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants
por: Geldhof, Vincent, et al.
Publicado: (2014)

New Oral Anticoagulants for the Treatment of Venous Thromboembolism: Understanding Differences and Similarities
por: Dobesh, Paul P., et al.
Publicado: (2014)

Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients
por: Song, Andrew B, et al.
Publicado: (2019)

Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants
por: Ay, C, et al.
Publicado: (2019)

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants
por: Weitz, Jeffrey I., et al.
Publicado: (2017)

The Use of Direct Oral Anticoagulants in the Management of Venous Thromboembolism in Patients With Obesity
por: Younis, Moustafa, et al.
Publicado: (2020)

Arguments for Using Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism
por: Chiorescu, Roxana Mihaela, et al.
Publicado: (2021)

Role of Direct Oral Anticoagulants for Post-operative Venous Thromboembolism Prophylaxis
por: Tun, Han Naung, et al.
Publicado: (2022)

Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era
por: Toth, Peter P
Publicado: (2016)

Efficacy of Direct Oral Anticoagulant into the Care of Venous Thromboembolism Related to Kumamoto Earthquake
por: Matsukawa, Mai, et al.
Publicado: (2018)

Efficacy and Safety of Direct Oral Anticoagulants for Risk of Cancer-Associated Venous Thromboembolism
por: Zeng, Jie, et al.
Publicado: (2019)

Current Management of Cancer-associated Venous Thromboembolism: Focus on Direct Oral Anticoagulants
por: Kim, Sang-A, et al.
Publicado: (2019)

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants
por: Wallvik, Niklas, et al.
Publicado: (2020)

New Oral Anticoagulants Open New Horizons for Cancer Patients with Venous Thromboembolism
por: Wumaier, Kaidireyahan, et al.
Publicado: (2022)

Trends in the Use of Oral Anticoagulants for Adults With Venous Thromboembolism in the US, 2010-2020
por: Iyer, Geetha S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dqsqv6h1ra7hr8v9eolkcbcs2g